Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mg
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bioequivalence, AUC, Cmax, Pharmacokinetics
Conditions
Bioequivalence, AUC, Cmax, Pharmacokinetics
Trial Timeline
Oct 11, 2016 → Nov 19, 2016
NCT ID
NCT03121820About Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mg
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mg is a phase 1 stage product being developed by GEROPHARM for Bioequivalence, AUC, Cmax, Pharmacokinetics. The current trial status is completed. This product is registered under clinical trial identifier NCT03121820. Target conditions include Bioequivalence, AUC, Cmax, Pharmacokinetics.
What happened to similar drugs?
1 of 1 similar drugs in Bioequivalence, AUC, Cmax, Pharmacokinetics were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03121820 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence, AUC, Cmax, Pharmacokinetics